news
Takeda enters agreement with F-star Therapeutics to license bispecific antibody
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
List view / Grid view
Takeda
article
Could metabo-oncology be the treatment modality of the future?
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
news
Takeda launches contract R&D firm AXCELEAD
Takeda has launched a contract research and development company, AXCELEAD, at its Shonan Research Centre.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
Crescendo Biologics and Takeda collaborate on $790 million cancer research
12 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Crescendo will use its transgenic platform and engineering expertise to optimally configure Humabody candidates against multiple targets selected by Takeda....
news
Takeda to enrol 5000 patients in giant multiple myeloma trial
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…